このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

健康なボランティアにおけるBCD101の安全性および薬物動態試験

2026年9月28日 更新者:Bichedam Co., Ltd.

健常成人ボランティアにおけるBCD101の安全性、忍容性および薬物動態特性を評価するための無作為化、二重盲検、単回/反復投与、用量漸増、第1相臨床試験

A randomized, double-blinded, single/multiple dosing, dose escalation Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of BCD101 in healthy adult volunteers.

The primary objectives of this study are to determine:

  1. The safety and tolerability of BCD101 in healthy adult volunteers.
  2. The pharmacokinetic profile of BCD101 following single and multiple dosing.

A control group is included, and dose cohorts will be compared to assess dose-dependent differences in safety, tolerability, and pharmacokinetics.

Key study activities include:

  1. Administration of single and multiple escalating doses of BCD101 and placebo under controlled conditions.
  2. Safety and tolerability assessments, including monitoring for adverse events (AEs), serious adverse events (SAEs), adverse drug reactions (ADRs), and serious adverse drug reactions (SADRs).
  3. Pharmacokinetic (PK) analysis to evaluate the pharmacokinetic characteristics of the investigational product.

調査の概要

状態

完了

条件

介入・治療

研究の種類

介入

入学 (実際)

57

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • North Chungcheong
      • Cheongju-si、North Chungcheong、韓国、28644
        • Chungbuk National University Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

19年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

  1. Inclusion Criteria

    • Healthy adult volunteers aged 19 years or older at screening.

    • Body weight ≥ 50.0 kg and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at screening.

      * BMI (kg/m²) = weight (kg) / {height (m)}²

    • No congenital or chronic medical conditions requiring treatment, and no pathological signs or findings upon medical examination.

    • Clinical laboratory tests, vital signs, physical examination, and 12-lead electrocardiogram (ECG) results at screening indicate suitability for participation based on the characteristics of the investigational medicinal product.

    • Fully understood the detailed explanation of this clinical trial, voluntarily agreed to participate, and provided written informed consent agreeing to comply with study requirements during the trial period.

  2. Exclusion Criteria

    • History or current clinically significant liver, kidney, neurological, psychiatric, respiratory, endocrine, hematological, neoplastic, genitourinary, cardiovascular, gastrointestinal, or musculoskeletal disorders.

    • Female subjects who are pregnant (urine hCG positive) or breastfeeding.

    • History of hypersensitivity (e.g., anaphylaxis, angioedema) or clinically significant allergic reactions to the active ingredient, excipients of the investigational product, or other medications (e.g., aspirin, penicillin antibiotics, macrolide antibiotics).

    • History of gastrointestinal diseases or surgeries that could affect absorption of the investigational drug (e.g., Crohn's disease, ulcers, acute or chronic pancreatitis), except simple appendectomy or hernia surgery.

    • Clinically significant abnormalities on 12-lead ECG at screening, including:

      • QTc interval > 450 ms (males) or > 470 ms (females)
      • PR interval > 200 ms
      • QRS duration > 120 ms
    • Clinically significant laboratory abnormalities at screening, including:

      • Liver function tests (AST, ALT, ALP, γ-GT, total bilirubin) exceeding twice the upper limit of normal.
      • Serum creatinine outside the reference range or estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m² as calculated by the CKD-EPI formula.
    • History of substance abuse or positive urine drug screening for abuse substances.

Vital signs at screening after at least 3 minutes of rest in a seated position meet any of the following:

  • Systolic blood pressure ≤ 90 mmHg or ≥ 150 mmHg

  • Diastolic blood pressure ≤ 60 mmHg or ≥ 100 mmHg

  • Pulse rate ≤ 40 bpm or ≥ 100 bpm

    • Evidence of orthostatic hypotension at screening.
    • Use of enzyme-inducing or inhibiting drugs such as barbiturates within 1 month prior to first dosing.
    • Abnormal diet or consumption of foods that could affect drug absorption, distribution, metabolism, or excretion.
    • Use of prescription or herbal medications that may affect the investigational product's characteristics within 2 weeks prior to first dosing, or over-the-counter drugs or dietary supplements within 10 days prior to first dosing (except when judged by the investigator not to affect the pharmacokinetics of the investigational product).
    • Participation in another clinical trial with investigational drug administration within 6 months prior to first dosing (the end date of participation is calculated as the day after the last dose of the previous trial).
    • Whole blood donation within 2 months prior to first dosing, platelet donation within 1 month prior to first dosing, blood transfusion within 1 month prior to first dosing, or inability to abstain from blood donation from informed consent to PSV.
    • Excessive alcohol consumption (more than 21 units per week; 1 unit = 10 g = 12.5 mL pure alcohol) within 6 months prior to first dosing or inability to abstain from alcohol from informed consent to PSV.
    • Smoking more than 10 cigarettes per day within 3 months prior to first dosing or inability to abstain from smoking from 24 hours prior to first dosing until last blood sampling.
    • Consumption of grapefruit-containing foods within 72 hours prior to first dosing or inability to abstain until PSV.
    • Consumption of caffeine-containing foods or beverages (e.g., coffee, green tea, black tea, carbonated drinks, coffee milk, energy drinks) from 24 hours prior to first dosing until last blood sampling or inability to abstain.
    • Engaging in strenuous exercise exceeding daily activity levels from 48 hours prior to first dosing until PSV or inability to refrain from such exercise.
    • Planning to become pregnant or not using reliable contraception methods (e.g., hormonal contraceptives, intrauterine device, sterilization procedures, barrier methods) for self or partner from informed consent until 90 days after last dose of investigational product.
    • Any other reasons deemed by the investigator to make the subject unsuitable for participation.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:順次割り当て
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:SAD-1(Treatment group)

6 Participants in the SAD-1(Treatment group) arm received a single oral dose of BCD101-1(2 sachets).

BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at low concentration.

[MAD] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at low concentration.

実験的:SAD-2(Treatment group)

6 Participants in the SAD-2(Treatment group) arm received a single oral dose of BCD101-2(2 sachets).

BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration.

[MAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration.

実験的:SAD-3(Treatment group)

6 Participants in the SAD-3(Treatment group) arm received a single oral dose of BCD101-2(3 sachets).

BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration.

[MAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration.

実験的:SAD-4(Treatment group)

6 Participants in the SAD-4(Treatment group) arm received a single oral dose of BCD101-2(4 sachets).

BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration.

[MAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration.

実験的:MAD-1(Treatment group)

6 Participants in the MAD-1(Treatment group) arm received BCD101-1(1 sachet), administered orally twice daily for 7 consecutive days.

BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

[SAD] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at low concentration.

[MAD] A liquid formulation of BCD101-1 containing 2 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at low concentration.

実験的:MAD-2(Treatment group)

6 Participants in the MAD-2(Treatment group) arm received BCD101-2(1 sachet), administered orally twice daily for 7 consecutive days.

BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

[SAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for single dosing at high concentration.

[MAD] A liquid formulation of BCD101-2 containing 4 g of the active ingredient per 10 g sachet, administered orally. Used for multiple dosing at high concentration.

実験的:MAD-3(Treatment group)

6 Participants in the MAD-3(Treatment group) arm received a combination of BCD101-1(1 sachet) and BCD101-2(1 sachet), administered orally twice daily for 7 consecutive days.

BCD101-1 is a low-dose liquid formulation containing 2 g of the active ingredient per 10 g sachet, while BCD101-2 is a high-dose liquid formulation containing 4 g of the active ingredient per 10 g sachet.

This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

[MAD] A combination of BCD101-1(2 g) and BCD101-2(4 g) liquid formulations, administered orally as separate sachets simultaneously. Used for multiple dosing.

実験的:SAD-1(Placebo group)

2 Participants in the SAD-1(Placebo group) arm received a single oral dose of BCD101-P(2 sachets).

BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-1, containing no active ingredient.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

実験的:SAD-2(Placebo group)

2 Participants in the SAD-2(Placebo group) arm received a single oral dose of BCD101-P(2 sachets).

BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

実験的:SAD-3(Placebo group)

2 Participants in the SAD-3(Placebo group) arm received a single oral dose of BCD101-P(3 sachets).

BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

実験的:SAD-4(Placebo group)

2 Participants in the SAD-4(Placebo group) arm received a single oral dose of BCD101-P(4 sachets).

BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient.

This study was conducted as a randomized, double-blinded, placebo-controlled, oral, single-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

実験的:MAD-1(Placebo group)

2 Participants in the MAD-1(Placebo group) arm received BCD101-P(1 sachet), administered orally twice daily for 7 consecutive days.

BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-1, containing no active ingredient.

This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

実験的:MAD-2(Placebo group)

2 Participants in the MAD-2(Placebo group) arm received BCD101-P(1 sachet), administered orally twice daily for 7 consecutive days.

BCD101-P is a placebo liquid formulation identical in appearance and volume to BCD101-2, containing no active ingredient.

The study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

実験的:MAD-3(Placebo group)

2 Participants in the MAD-3(Placebo group) arm received BCD101-P(2 sachets), administered orally twice daily for 7 consecutive days.

BCD101-P is a placebo liquid formulation identical in appearance and volume to the active formulations, containing no active ingredient.

This study was conducted as a randomized, double-blinded, placebo-controlled, multiple-dose, dose-escalation trial.

[SAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for single dosing.

[MAD Placebo] A placebo liquid formulation matching the appearance and volume of BCD101 sachets, containing no active ingredient. Administered orally. Used for multiple dosing.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants With Adverse Events (Single-Ascending Dose, SAD)
時間枠:Day -1, Day 1, post-study visit (Day 4-7)

All adverse events occurring during the clinical trial following a single ascending dose of BCD101 will be collected and evaluated for seriousness, severity, and their relationship to the investigational product. Events will be coded using MedDRA System Organ Class and Preferred Term.

Day -1, Day 1, post-study visit (Day 4-7)
Physical Examination Abnormalities (SAD)
時間枠:Screening, Day -1, Day 1, post-study visit (Day 4-7)

A complete physical examination will be performed, and findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as abnormalities for this outcome measure. Non-clinically significant deviations (NCS) will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

Screening, Day -1, Day 1, post-study visit (Day 4-7)
Vital signs: Systolic and Diastolic Blood Pressure (SAD)
時間枠:Screening, Day -1, Day 1, post-study visit (Day 4-7)

Systolic and diastolic blood pressure will be measured after at least three minutes of rest in the seated position.

Screening, Day -1, Day 1, post-study visit (Day 4-7)
Vital signs: Heart Rate (SAD)
時間枠:Screening, Day -1, Day 1, post-study visit (Day 4-7)

Heart rate will be measured after at least three minutes of rest in the seated position.

Screening, Day -1, Day 1, post-study visit (Day 4-7)
Vital signs: Body Temperature (SAD)
時間枠:Screening, Day -1, Day 1, post-study visit (Day 4-7)

Body temperature will be measured after at least three minutes of rest in the seated position.

Screening, Day -1, Day 1, post-study visit (Day 4-7)
Electrocardiogram (ECG) Abnormalities (SAD)
時間枠:Screening, Day -1, Day 1, post-study visit (Day 4-7)

A standard 12-lead electrocardiogram will be performed, and ECG findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as ECG abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

Screening, Day -1, Day 1, post-study visit (Day 4-7)
Laboratory Abnormalities (SAD)
時間枠:Screening, Day -1, Day 1, post-study visit (Day 4-7)

Clinical laboratory tests will include hematology, clinical chemistry, urinalysis, serology, and urine drug screening. Laboratory findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as laboratory abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

Screening, Day -1, Day 1, post-study visit (Day 4-7)
Number of Participants With Adverse Events (MAD)
時間枠:Day -1 through Day 7, and post-study visit (Day 8-12)

All adverse events occurring during the clinical trial following a multiple ascending dose of BCD101 will be collected and evaluated for seriousness, severity, and their relationship to the investigational product. Events will be coded using MedDRA System Organ Class and Preferred Term.

Day -1 through Day 7, and post-study visit (Day 8-12)
Physical Examination Abnormalities (MAD)
時間枠:Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)

A complete physical examination will be performed, and findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as abnormalities for this outcome measure. Non-clinically significant deviations (NCS) will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)
Vital signs: Systolic and Diastolic Blood Pressure (MAD)
時間枠:Screening, Day -1 through Day 7, and post-study visit (Day 8-12)

Systolic and diastolic blood pressure will be measured after at least three minutes of rest in the seated position.

Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
Vital signs: Heart Rate (MAD)
時間枠:Screening, Day -1 through Day 7, and post-study visit (Day 8-12)

Heart rate will be measured after at least three minutes of rest in the seated position.

Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
Vital signs: Body Temperature (MAD)
時間枠:Screening, Day -1 through Day 7, and post-study visit (Day 8-12)

Body temperature will be measured after at least three minutes of rest in the seated position.

Screening, Day -1 through Day 7, and post-study visit (Day 8-12)
Electrocardiogram (ECG) Abnormalities (MAD)
時間枠:Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)

A standard 12-lead electrocardiogram will be performed, and ECG findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as ECG abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

Screening, Day -1, Day 1, Day 7, post-study visit (Day 8-12)
Laboratory Abnormalities (MAD)
時間枠:Screening, Day -1, Day 1, Day 6-7, post-study visit (Day 8-12)

Clinical laboratory tests will include hematology, clinical chemistry, urinalysis, serology, and urine drug screening. Laboratory findings will be categorized as normal, not clinically significant (NCS), or clinically significant (CS). Only clinically significant (CS) findings will be classified as laboratory abnormalities for this outcome measure. Non-clinically significant deviations (NCS) from reference ranges will not be classified as abnormalities. The number of participants with clinically significant abnormalities will be reported.

Screening, Day -1, Day 1, Day 6-7, post-study visit (Day 8-12)

二次結果の測定

結果測定
メジャーの説明
時間枠
Pharmacokinetic Parameters: Maximum Plasma Concentration (Cmax) (SAD)
時間枠:Day 1 (pre-dose through 12 hours post-dose)

Cmax will be determined from the plasma concentration-time profile following a single ascending dose of BCD101.

Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration (AUC0-t) (SAD)
時間枠:Day 1 (pre-dose through 12 hours post-dose)

AUC0-t will be calculated using non-compartmental analysis following a single ascending dose of BCD101.

Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUCinf) (SAD)
時間枠:Day 1 (pre-dose through 12 hours post-dose)

AUCinf will be calculated using non-compartmental analysis from the plasma concentration-time profile following a single ascending dose of BCD101.

Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration (Tmax) (SAD)
時間枠:Day 1 (pre-dose through 12 hours post-dose)

Tmax will be determined from the plasma concentration-time profile following a single ascending dose of BCD101.

Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Terminal Elimination Half-Life (t1/2) (SAD)
時間枠:Day 1 (pre-dose through 12 hours post-dose)

Terminal elimination half-life will be estimated from the terminal phase of the plasma concentration-time profile following a single ascending dose of BCD101.

Day 1 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Maximum Plasma Concentration at Steady State (Cmax,ss) (MAD)
時間枠:Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

Cmax,ss will be determined from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101.

Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameters: Area Under the Concentration-Time Curve Over the Dosing Interval (AUCtau,ss) (MAD)
時間枠:Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

AUCtau,ss will be calculated at steady state during multiple ascending dosing (Day 1-7).

Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Area Under the Concentration-Time Curve From Time Zero to Infinity at Steady State (AUCinf,ss) (MAD)
時間枠:Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

AUCinf,ss will be calculated using non-compartmental analysis from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101.

Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Time to Maximum Plasma Concentration at Steady State (Tmax,ss) (MAD)
時間枠:Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

Tmax,ss will be determined from the plasma concentration-time profile at steady state following multiple ascending doses of BCD101.

Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Terminal Elimination Half-Life at Steady State (t1/2,ss) (MAD)
時間枠:Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)

Terminal elimination half-life at steady state will be estimated from the terminal phase of the plasma concentration-time profile following multiple ascending doses of BCD101.

Day 1 (pre-dose through 12 hours post-dose), Day 5 (pre-dose), Day 6 (pre-dose), Day 7 (pre-dose through 12 hours post-dose)
Pharmacokinetic Parameter: Accumulation Ratio (Rac) (MAD)
時間枠:Day 1 (pre-dose through 12 hours post-dose), Day 7 (pre-dose through 12 hours post-dose)

Rac will be calculated to assess the accumulation of BCD101 following multiple ascending doses.

Day 1 (pre-dose through 12 hours post-dose), Day 7 (pre-dose through 12 hours post-dose)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年9月22日

一次修了 (実際)

2026年5月15日

研究の完了 (実際)

2026年5月15日

試験登録日

最初に提出

2025年11月17日

QC基準を満たした最初の提出物

2025年12月1日

最初の投稿 (実際)

2025年12月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月29日

QC基準を満たした最後の更新が送信されました

2026年9月28日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • BCD101

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。